Ionis Pharmaceuticals IONS Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's stock-based comp?
- Ionis Pharmaceuticals (IONS) reported stock-based comp of $43.28M in Q1 2026.
- How has Ionis Pharmaceuticals's stock-based comp changed year-over-year?
- Ionis Pharmaceuticals's stock-based comp increased by 45.6% year-over-year, from $29.72M to $43.28M.
- What is the long-term trend for Ionis Pharmaceuticals's stock-based comp?
- Over 4 years (2021 to 2025), Ionis Pharmaceuticals's stock-based comp has grown at a 2.6% compound annual growth rate (CAGR), from $120.68M to $133.87M.
- What does stock-based comp mean?
- The non-cash cost of paying employees with company stock.
- How do you interpret stock-based comp?
- Rising levels indicate a strategy to align employee interests with shareholders, though it results in potential dilution.
- How does stock-based comp compare across companies?
- Standard across the technology and biotech sectors for talent retention.